Lutetium Lu-177 dotatate is a SSTR-targeted radiopeptide. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Lutetium Lu-177 dotatate has an FDA-approved product on the U.S. market, marketed as Lutathera under application NDA208700.
The current label is held by Advanced Accelerator Applications USA, Inc.
From the FDA label
is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.Quoted from the FDA-approved prescribing information
The evidence
One source on Lutetium Lu-177 dotatate, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Lutetium Lu-177 dotatate. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides